Collegium Pharmaceutical, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $62.9M | $69.2M | $48.2M | $-25.0M | $71.5M | $26.8M | $-22.7M | $-39.1M |
| Depreciation & Amortization | — | — | — | — | — | — | $731.0K | $1.1M |
| Depreciation | $4.2M | $3.9M | $3.5M | $2.7M | $1.7M | $870.0K | $731.0K | $1.1M |
| Amortization | $221.9M | $165.3M | $145.8M | — | $67.2M | $60.7M | $14.8M | $109.8M |
| Stock-Based Compensation | $41.9M | $32.4M | $27.1M | $22.9M | $24.3M | $21.9M | $16.5M | $13.8M |
| Net Cash from Operating Activities | $329.3M | $205.0M | $274.7M | $124.2M | $103.6M | $93.9M | $27.8M | $169.4M |
| Investing Activities | ||||||||
| Capital Expenditures | $1.7M | $1.7M | $461.0K | $1.6M | $1.9M | $5.5M | $6.4M | $5.5M |
| Business Acquisitions | $0 | $267.5M | $0 | $572.1M | — | — | — | — |
| Net Cash from Investing Activities | $-63.5M | $-287.8M | $-70.8M | $-573.7M | $-1.9M | $-373.8M | $-6.4M | $-24.4M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $25.1M | $60.0M | $75.0M | $14.1M | $47.9M | — | — | — |
| Net Cash from Financing Activities | $-110.2M | $-60.6M | $-140.2M | $436.7M | $-89.3M | $286.5M | $2.0M | $-117.2M |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | $327.6M | $203.3M | $274.3M | $122.6M | $101.6M | $88.4M | $21.3M | $163.9M |